We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other dividend stocks.
Dividend stocks, while popular among investors, have been underperforming for a while. Dan Lefkovitz, a strategist at Morningstar Indexes, attributed this lag to a straightforward reason: their limited exposure to the technology sector. Although technology wasn’t the top-performing sector in 2024, it came close and now represents a significant portion of the market.
However, this doesn’t suggest that dividend stocks are fundamentally weak or that they won’t rebound in the future. Alex Bryan, Morningstar’s director of product management for equity indexes, believes that changing market dynamics could benefit dividend investors. Here are some comments from the analyst:
“From a valuation standpoint, dividends look more attractive than they did a year ago, and that’s partially because of the relative underperformance that they’ve had. Bonds are certainly more competitive relative to dividends. But if you look at dividend-paying stocks relative to the rest of the equity markets, I think they’re becoming more attractive relative to other stocks.”
Other analysts also suggested that dividend-paying stocks might stage a comeback in 2025 due to growing investor demand for cash returns. The broader market’s dividend yield fell below 1.19% in 2024, marking a 20-year low, compared to its long-term average of 4.3%. With interest rates recovering on risk-free investments like Treasurys, companies are facing increased competition for yield. As a result, many are raising dividends or initiating them for the first time. Notably, some major tech giants began paying dividends in 2024, signaling to the market their shift toward value positioning within a high-growth sector.
Also read: 10 Best High-Yield Dividend Stocks To Invest In
In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free cash flow to shareholders, as reported by Bloomberg. The average dividend yield for these companies was approximately 2.3%, while the market capitalization-weighted yield stood at about 1.5%.
Wolfe Research’s Chief Investment Strategist, Chris Senyek, offers a unique perspective on investing in dividend stocks. While investors typically focus on companies with growing dividends and high yields, Senyek suggested exploring other opportunities. He highlighted companies initiating dividends for the first time and those that have recently reduced their payouts. Initiating a dividend indicates management’s confidence in maintaining steady earnings and cash flow, while also attracting a new group of investors.
Senyek also noted that shares of companies that cut dividends tend to underperform leading up to the cut, perform in line with the market shortly after, and begin to outperform about six months later. The key is to identify companies that may be at risk of cutting dividends and to reconsider those that reduced payouts a few months earlier. To forecast potential cuts, Senyek examines companies with high dividend yields, substantial debt, and elevated payout ratios. For potential new dividend payers, Senyek seeks out companies with robust free cash flow yields that are actively repurchasing shares and maintaining manageable debt levels. In view of this, we will take a look at stocks with steady dividends.
Our Methodology:
For this article, we scanned Insider Monkey’s database of 900 hedge funds as of Q3 2024 and picked dividend stocks with over 10 consecutive years of dividend growth. From this list, we further refined our selection criteria by identifying stocks with a projected upside potential of over 10% based on analyst price targets, as of January 20. The stocks are ranked according to their upside potential. We also considered hedge fund sentiment around each stock using Insider Monkey’s data for Q3 2024.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist.
AbbVie Inc. (NYSE:ABBV)
Upside Potential as of January 20: 18.03%
AbbVie Inc. (NYSE:ABBV) is an Illinois-based biopharmaceutical company that specializes in the development and commercialization of advanced therapies and treatments in various areas of healthcare. The company continues to be a key player in the pharmaceutical industry, supported by a strong portfolio of existing products and promising candidates in its pipeline. One standout is Tavapadon, a treatment for Parkinson’s disease, which recently achieved significant milestones in a late-stage study, offering hope for ABBV’s neuroscience initiatives.
Although pharmaceutical stocks have encountered difficulties in 2024, largely due to political concerns over drug pricing, AbbVie Inc. (NYSE:ABBV)’s focus on creating new, innovative treatments has positioned it strongly. The Inflation Reduction Act, which limits price increases, has pushed companies to prioritize innovation instead of relying on price hikes. The company’s successful efforts to diversify its portfolio in recent years have positioned the company for substantial growth moving forward. In the past 12 months, the stock has surged by nearly 5%.
In the third quarter of 2024, AbbVie Inc. (NYSE:ABBV) reported revenue of $14.46 billion, which saw a 4% increase from the same period last year. Its Immunology Portfolio generated over $7 billion, also growing by 4%. Moreover, in August 2024, AbbVie completed an $8.7 billion acquisition of Cerevel Therapeutics, a neuroscience company.
While AbbVie Inc. (NYSE:ABBV) primarily focuses on immunology, oncology, inflammation, and eye care, its recent move into neuroscience has opened up additional growth opportunities, helping to diversify its revenue streams. For investors, the key focus should be on AbbVie’s robust pipeline in these other areas, which holds potential for future growth, regardless of how its neuroscience efforts unfold.
AbbVie Inc. (NYSE:ABBV) is one of the best stocks with steady dividends as the company has been rewarding shareholders with growing dividends for the past 52 years. The company pays a quarterly dividend of $1.64 per share and has a dividend yield of 3.79%, as of January 20.
At the end of the third quarter of 2024, 68 hedge funds tracked by Insider Monkey held stakes in AbbVie Inc. (NYSE:ABBV), up from 67 in the preceding quarter. These stakes are collectively valued at roughly $2.6 billion. With over 1.7 million shares, AQR Capital Management was the company’s leading stakeholder in Q3.
Overall ABBV ranks 8th on our list of the best dividend stocks with high yields. While we acknowledge the potential for ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stock To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.
